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Abstract  
        
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing 
for the approval of immediate release (IR) solid oral dosage forms containing prednisolone 
are reviewed. Data on its solubility, oral absorption, and permeability are not totally 
conclusive, but strongly suggest a BCS Class 1 classification. Prednisolone's therapeutic 
indications and therapeutic index, pharmacokinetics, and the possibility of excipient 
interactions were also taken into consideration. Available evidence indicates that a biowaiver 
for IR solid oral dosage forms formulated with the excipients tabulated in this article would be 
unlikely to expose patients to undue risks.  
 
INTRODUCTION 
        
A monograph based on literature data is presented on prednisolone with respect to its 
biopharmaceutical properties and the risk of waiving in vivo bioequivalence (BE) testing for 
the approval of new and/or reformulated immediate release (IR) solid oral dosage forms. The 
purpose and scope of these monographs has been discussed previously.[1] Briefly, the aim of 
these monographs is to evaluate all pertinent data available from literature sources for active 
pharmaceutical ingredients (APIs) on the WHO List of Essential Medicines,[2] to assess the 
appropriateness of such a biowaiver from the biopharmaceutical point of view and also from 
the perspective of public health. This systematic approach to recommend or advise against a 
biowaiver decision is referred to in the recently published WHO Guideline[3] stating that these 
monographs provide detailed information which should be taken into account whenever 
available in the biowaiver consideration. Monographs have already been published on 
acetaminophen (paracetamol),[4] amitriptyline,[5] atenolol,[1] chloroquine,[6] cimetidine,[7] 
ibuprofen,[8] propranolol,[1] ranitidine,[9] and verapamil.[1] 
 
EXPERIMENTAL 
 
Published information was obtained from PubMed, up to October 2005, and through the 
International Pharmaceutical Abstracts. Key words used were: prednisolone, prednisone, 
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corticosteroids, indication, solubility, polymorphism, partition coefficient, permeability, 
absorption, distribution, metabolism, excretion, dissolution, and excipients. 
 
GENERAL CHARACTERISTICS 
 
Prednisolone (INN) is a synthetic steroid that is chemically defined as 11,17,21-
trihydroxypregna-1,4-diene-3,20-dione. Its structure is shown in Figure 1.  
 
 
 
Figure 1. Structure of prednisolone C21H28O5, Molecular weight: 360.4. 
 
Therapeutic Indication, Dose, and Therapeutic Index 
Prednisolone is a well-known corticosteroid that is used to treat a wide variety of acute and 
chronic disorders, including arthritis, asthma, allergic diseases, hepatitis, congenital adrenal 
hyperplasia, systemic lupus erythematosus and certain haematological, infectious, cardiac, 
dermal, neurological, metabolic, gastrointestinal (GI) diseases as well as malignant diseases 
and many inflammatory states.[10-14] Furthermore, prednisolone is used intravenously at 
very high doses for the treatment of severe shock.[14] 
 
Prednisolone is used over a wide dose range. Low dose corticosteroid therapy is considered 
to include doses up to 10 mg prednisolone per day, being most commonly prescribed at 
approximately 5-7.5 mg/day. The dosage must be individualized and is highly variable 
depending on the nature and severity of the disease, and on patient response. There is no 
absolute maximum dosage, however, intensity and frequency of adverse events is observed 
to rise with increasing dose. Prednisolone is not considered to be a narrow therapeutic index 
drug and there is generally no need to monitor blood levels. However, for severe diseases 
that require very high doses of prednisolone, a monitoring of blood levels may be 
advisable.[14] 
 
A special consideration that should be given in prednisolone therapy is to follow appropriate 
procedures for withdrawing chronically treated patients from high doses of the drug. The 
strategy to withdraw the patient from systemic corticosteroids depends on the period of 
treatment and the likelihood of the disease to relapse. In patients who have received systemic 
corticosteroids for more than 3 weeks at high doses, withdrawal should be gradual[14],[15] in 
order to allow the hypothalamo-pituitary-adrenal (HPA) axis to recover. Abrupt withdrawal of 
systemic corticosteroid treatment which has continued for up to 3 weeks may be appropriate if 
the disease is unlikely to relapse[16],[17] and is unlikely to lead to clinically relevant HPA-axis 
suppression.[18] In cases where a dose tapering schedule is appropriate, up to date 
recommendations can be found in the recent literature.[14] Low dose corticosteroid therapy 
can generally be terminated without dose tapering although a gradual withdrawal is often 
recommended. 
 
PHYSICO-CHEMICAL PROPERTIES 
 
Esters and Salts 
Several esters of prednisolone are available. Apart from prednisolone itself, the USP 28 
includes prednisolone acetate, prednisolone hemisuccinate, prednisolone sodium phosphate, 
prednisolone sodium succinate, and prednisolone tebutate,[19] while the EP 5th edition 
monographs prednisolone acetate, prednisolone pivalate, and prednisolone sodium 
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phosphate.[20] Ester compounds currently having a marketing authorization (MA) in Germany 
(DE) are prednisolone hydrogen succinate, prednisolone sodium phosphate, and 
prednisolone acetate.[12] This monograph pertains to prednisolone itself, but not to ester 
forms. 
 
Polymorphism 
Prednisolone exhibits polymorphism.[20] Two forms have been characterized.[21],[22] 
Prednisolone also forms solvates with water and chloroform (pseudo-polymorphism).[19],[22] 
USP 28 monographs both the anhydrous form and the sesquihydrate.[19] This monograph 
pertains both to prednisolone anhydrous and the sesquihydrate. 
 
Solubility 
Prednisolone is very slightly soluble in water (1 g dissolves in 1000-10000 mL).[20] An 
aqueous solubility ranging from 0.22 to 0.24 mg/mL has been reported (without indicating the 
temperature),[23],[24] which is in accordance with a value of 243 µg/mL that was measured at 
25°C.[25] Table 1 summarizes solubility data available in the literature, together with the 
corresponding dose:solubility ratio. The WHO maximum dose strength is 5 mg.  
 
   
Table 1. Solubility (mg/mL) of Prednisolone at 25°C[25] and Dose: Solubility Ratios 
(D/S) (mL) for Four Strengths Covering the Extremes of the Range  
 
 
Medium Solubility D/S (1 mg) D/S (5 mg) D/S (10 mg) D/S (50 mg) 
 
Water 0.243 mg/mL 4.1 mL 21 mL 41 mL 206 mL 
 
 
 
Five milligrams reflects the WHO maximum dose strength. The critical limit for D/S at 37°C is 
<250 mL.[3],[72-74] 
 
 
Partition Coefficient 
LogP values of 1.59 and 1.62 have been reported.[23],[26],[27] Calculated values obtained by 
different methods range from 1.38 to 1.49[27],[28] and from 2.5 to 3.5.[29] 
 
pKa 
The chemical structure of prednisolone (see Fig. 1) does not provide any acid or basic 
elements, and hence is a neutral substance and no reference to a pKa value was found in the 
literature. 
 
Dosage Form Strength 
Strengths of IR solid oral dosage forms with a current MA in DE are 1, 2, 2.5, 5, 10, 20, and 
50 mg, in Finland (FI) 5, 20, and 40 mg and in The Netherlands (NL) 5, 20, 30, and 50 mg, 
see Table 2.  
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Table 2. Excipients* Present in Prednisolon IR Solid Oral Drug Products with a 
Marketing Authorization (MA) in Germany (DE), Finland (FI), and The Netherlands (NL), 
and the Minimal and Maximal Amount of That Excipient Present Pro Dosage Unit in 
Solid Oral Drug Products with a MA in the USA 
 
Excipient 
Drug Products Containing That Excipient with 
a MA Granted by the Named Country 
Range Present in Solid Oral Dosage 
Forms with a MA in the USA (mg) 
 
Calcium stearate FI(1) 0.7-43a 
Castor oil hydrogenated FI(1) 0.93-37.6a 
Cellulose DE(2-5) FI(1,6,7) NL(8) 4.6-1385a 
Copovidone FI(1) 86-500 
Croscarmellose sodium DE(3) FI(6,7) 2-180 
Crospovidone FI(1) 4.4-792a 
Gelatin DE(9) 1-756a 
Hydroxypropylcellulose DE(10) 1-132 
Hypromellose DE(2,3,11,12) 0.8-80 
Lactose DE(2-5,9-22) FI(1) NL(8,23-28) 23-1020a 
Magnesium stearate DE(2-5,9-22) FI(6,7) NL(8,23-28) 0.9-401a 
Maize starch DE(2-5,11,12) NL(28) 9.9-1135a 
Mannitol FI(6,7) 10-454 
Potato starch DE(9,13,14,16-18,20-22) NL(23-27) 2.1-80 
Potato starch 
(pregelatinized) 
NL(23-25,27)  
Povidone FI(6,7) NL(8,26) 0.17-75 
Silica DE(2-5,10-14,16-18,20-22) FI(1,6,7) NL(23-27) 0.65-99 
Sodium lauryl sulfate DE(5) 0.65-50 
Sodium starch glycolate DE(2,9-22) NL(8,23-25,27,28) 2-876a 
Starch, pregelatinized NL(28) 6.6-600 
Talc DE(2,9,11,12) FI(1) NL(8,26) 0.1-220a 
 
 
 
 
Sources of data: DE: www.rote-liste.de (April 4, 2006); FI: www.nam.fi (April 5,2006); NL: 
www.cbg-meb.nl. (April 3, 2006). USA: http://www.fda.gov/cder/iig/iigfaqWEB.htm#purpose 
(IIGQInte.txt version date 02-02-2006). 
  * Colorants, flavors, and ingredients present in printing ink only are not included. 
  a The upper range value reported is unusual high for IR solid oral dosage forms and the 
authors doubt its correctness. 
   1 PREDNISOLON 5 mg.  
2 Decortin® H 1 mg.  
3 Prednisolon 20 mg/-50 mg JENAPHARM®.  
4 Prednisolon-ratiopharm® 5 mg Tabletten.  
5 Prednisolon-ratiopharm® 50 mg Tabletten.  
6 PREDNISOLON 40 mg.  
7 PREDNISOLON 20 mg.  
8 Prednisolon 30 mg, tabletten.  
9 Prednisolon 1 mg/-5 mg JENAPHARM®.  
10 Prednisolon 2 mg GALEN®.  
11 Decortin® H 5 mg/-20 mg/-50 mg.  
12 Duraprednisolon 5 mg.  
13 Decortin® H 10 mg.  
14 Dermosolon 5 mg/-10 mg/-20 mg/-50 mg.  
15 Hefasolon®.  
16 PredniHEXAL® 5 mg/-10 mg/-20 mg/-50 mg Tabletten.  
17 Predni H Tablinen® 5 mg/-50 mg.  
18 Predni H Tablinen® 20 mg.  
19 Prednisolon 2,5/-5-Rotexmedica.  
20 Prednisolon 5 mg/-20 mg/-50 mg GALEN®.  
21 Prednisolon acis® 5 mg/-10 mg/-20 mg/-50 mg.  
22 Prednisolon AL 5 mg/-10 mg/-20 mg/-50 mg Tabletten.  
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23 Prednisolon 20 PCH, tabletten 20 mg.  
24 Prednisolon 30 mg PCH, tabletten.  
25 Prednisolon 50 PCH, tabletten 50 mg.  
26 Prednisolon CF 5 mg, tabletten.  
27 Prednisolon 5 PCH, tabletten 5 mg.  
28 Prednisolon ratiopharm 5 mg, tabletten.  
 
PHARMACOKINETIC PROPERTIES 
 
Absorption and Bioavailability (BA) 
Following oral intake prednisolone is rapidly absorbed from the GI tract. The systemic 
availability is almost complete and reported to range from 75% to 98%,[11],[14],[30-39] with a 
concentration-time profile that is very similar to that when prednisone is taken orally.[40],[41] 
Maximum serum concentrations occur within 1-2 h after administration of a single 
dose.[10],[11],[14],[31],[32],[35],[42-44] Food intake prolongs the time to peak concentration, 
but does not affect the extent of absorption.[45-47] No indication of existence of an absorption 
window was found in the literature. 
 
Permeability 
An apparent permeability coefficient of 2 × 10-5 cm/s was measured in Caco-2 cells.[28] 
Using artificial phospholipid membranes, a value of 0.2 × 10-6 cm/s was reported.[48] 
 
Distribution 
The volume of distribution of prednisolone was reported as 0.22-0.70 L/kg.[31],[44],[49] With 
increasing dose, the volume of distribution of prednisolone increases, due to a shift in a larger 
fraction of the body burden from the plasma compartment to other body tissues or to sites of 
greater metabolic activity.[44] The concentration-dependent binding of prednisolone to the 
plasma proteins (i.e., transcortin and albumin) results in the dose-dependent nonlinear 
pharmacokinetics observed for prednisolone.[11],[50],[51] Transcortin has high affinity and 
low capacity binding sites while albumin has low affinity and a high capacity for binding 
prednisolone. The fraction bound is not constant and decreases in a nonlinear fashion with 
increasing concentrations: at low concentrations protein binding appears to be quite high 
(80%-90%), but declines at higher prednisolone levels to 60%-70%.[33],[44],[49],[50],[52] For 
plasma concentrations of up to 400 ng/mL an approximate linear function of fraction bound 
can be assumed, which switches over to a constant (lower) relation above 600 ng/mL,[44] 
reflecting the saturable binding of prednisolone to transcortin. Binding of prednisolone to 
plasma protein is independent of the route of administration.[51] 
 
Distribution and elimination of prednisolone have been described in terms of a two-
compartment open model, with rapid distribution within the first half-hour followed by a slower 
terminal elimination phase.[11],[36] 
 
Prednisolone is able to penetrate the blood-brain barrier, reaching about 1/10 of the serum 
concentration in cerebrospinal fluid. Like all glucocorticosteroids, prednisolone crosses the 
placenta.[14],[53] The use of prednisolone is usually compatible with breast feeding[54] since 
its concentrations in breast milk are minimal (<10% of serum level) and represents a 
negligible addition to the infants endogenous cortisol production.[55] 
 
Metabolism and Excretion 
Prednisolone is pharmacologically active and may be metabolized in a variety of tissues, 
including liver, lung, kidney, and skin.[14],[56],[57] Prednisolone is partially converted into 
prednisone, which is inactive. Both steroids undergo a reversible and dose-dependent 
metabolism. The interconversion equilibrium strongly favors the formation of 
prednisolone,[11],[40] resulting in a ratio of prednisolone to prednisone plasma concentrations 
of 4:1 to 10:1.[44],[58] The nonlinear interconversion varies with time and 
dose.[11],[31],[44],[49],[59-62] The serum half-life of prednisolone is known to be 2-4 
h,[10],[11],[32],[33],[39],[44],[46] and may be influenced by time of day, age, gender, physical 
exercise, pregnancy, drugs, and several diseases.[14] 
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Prednisolone is cleared from the body primarily by hepatic metabolism by hydroxylation and 
reduction forming metabolites which conjugate with glucuronic acid and sulfate.[11],[63] The 
most important unconjugated metabolite is 6-hydroxyprednisolone. Eleven metabolites of 
prednisolone and prednisone have been identified.[51] Certain metabolites were found in both 
the unconjugated and the conjugated forms in the urine, the percentage in the unconjugated 
being about twice as large as that in the conjugated. An appreciable proportion, 11%-24% of 
a given dose of prednisolone, can be recovered in urine unchanged. Approximately 2%-5% is 
excreted in the urine as prednisone.[44] 
 
The clearance of prednisolone is dose-dependent,[31-33],[44],[59],[60,64] due to the 
concentration-dependent protein binding, that is, at high doses the increased free fraction of 
prednisolone is reflected in a greater plasma clearance and apparent volume of distribution. 
The total body clearance of prednisolone has been reported to be 111 mL/min/1.73 m2 for a 5 
mg dose and 194 mL/min/1.73 m2 for a 40 mg dose of prednisolone.[35],[44] 
 
Renal elimination comprises 40% of total elimination.[65] The mean elimination half-life 
increases with the dose and ranges from 2.1 to 3.5 h.[11],[33],[66] The half-life in children is 
shorter than that recorded in most adult studies.[11] Children show no evidence of an 
abnormal prednisolone metabolism. Women appear to have a slightly higher clearance of 
prednisolone (around 18% higher)[67] and excrete significantly more 6-hydroxyprednisolone 
than men[51] - in step with the finding that estrogens enhance the hydroxylation of cortisol. 
 
DOSAGE FORM PERFORMANCE 
 
Excipients and/or Manufacturing Variations 
A wide range of excipients has been used in several formulations of IR prednisolone tablet 
products approved for marketing in DE, where the market leader is Decortin® H. Table 2 
shows the excipients used in IR prednisolone tablets with a MA in DE, FI, and NL. In view of 
these MAs, it is reasonable to expect that these formulations successfully passed an in vivo 
BE study. Indeed, a number of Summaries of Product Characteristics (SmPCs) with an MA in 
DE report results of successful in vivo BE studies.[68-70] Also, in view of the actual clinical 
use, it can be supposed that the excipients present in a large number of these drug products 
do not have a significant effect on the extent and rate of absorption of prednisolone, and 
hence no impact on its clinical use. One product from the German market contains sodium 
lauryl sulfate (Prednisolon-ratiopharm® 50). It is highly likely that the surfactant is included in 
order to ensure an appropriate dissolution rate of the drug. However, the SmPC of this 50 mg 
product containing sodium lauryl sulfate reports data showing in vivo BE to a reference 
product, at least with respect to the AUC.[69] Numerous other 50 mg products do not contain 
any surfactant and are not inferior concerning the rate and extent of absorption. In an 
aqueous medium at 37.5°C, magnesium trisilicate seems to adsorb prednisolone and the 
presence of magnesium oxide leading to chemical degradation.[71] However, these 
excipients are not part of any formulation currently on the market in the above-mentioned 
countries and the clinical relevance of the adsorption has never been demonstrated. By 
contrast, aluminum hydroxide, calcium carbonate, and magnesium carbonate do not seem to 
adsorb prednisolone. 
 
In Vivo Bioequivalence Studies 
Several studies have demonstrated BE in vivo among specific marketed prednisolone 
products.[14] In a randomized crossover study in 13 healthy volunteers, prednisolone tablet 
formulations of 2, 5, and 20 mg were found to be bioequivalent in vivo to a reference if the 
same dosage was administered.[39] Two studies designed as four-treatment crossover 
evaluations in 12 adult male volunteers found seven different commercially available 
prednisolone tablets bioequivalent in vivo; these products demonstrated in vitro dissolution of 
at least 75 % in 30 min.[43] 
 
Dissolution and In Vitro/In Vivo Correlation 
The USP 28 specification for dissolution of prednisolone tablets is not less than 70% (Q) 
dissolved in 30 min in 900 mL water, using the paddle at 50 rpm.[19] Prednisolone became 
official in USP 15 (Second Supplement, April 1959), and the monograph was extended by the 
content uniformity requirement in USP 17. USP 18 included a dissolution test in which 60% of 
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the labeled amount of prednisolone was required to dissolve in de-aerated water in not more 
than 20 min. In vitro/in vivo correlations were not found in the literature. 
 
DISCUSSION 
 
Solubility 
Solubility criteria defined in present regulatory guidances[3],[72-74] for classifying an API as 
highly soluble requires the highest dose strength to be soluble in 250 mL of water over the pH 
range of 1-7.5 at 37°C. The available data therefore do not provide all information necessary 
for BCS classification. Although solubility over this pH range can be assumed to be 
independent of pH (nonionizable drug), literature results were determined at 25°C rather than 
37°C. At 25°C, prednisolone meets already the dose:solubility ratio criterion of below 250 mL, 
that is, is highly soluble.[3],[72-74] It is reasonable to assume that prednisolone has an 
endothermic heat of solution and that the solubility at 37°C will be even higher. 
 
Permeability 
Numerous studies report averages of 80%-100% for the systemic availability of prednisolone 
following oral administration. Only very limited in vitro studies on the permeability of 
prednisolone could be located. One result, reporting a permeability of 0.2 × 10-6 cm/s, used 
artificial phospholipid membranes. Using the same system, for metoprolol a log permeability 
of about -5.2 was reported,[48] corresponding to 6.3 × 10-6 cm/s, suggesting the permeability 
of prednisolone to be slightly lower than the permeability of metoprolol, a substance often 
taken as reference for the criterion highly permeable drug substance.[29] Also, the logP of 
prednisolone seems to be slightly below the logP of metoprolol.[29] On the other hand, in 
Caco-2 cells, a permeability of 2 × 10-5 cm/s was reported,[28] and using the same system, 
for verapamil an apparent permeability of 1.5 × 10-5 cm/s was reported. As verapamil is 
assumed to be highly permeable,[1] prednisolone can thus be assumed as highly permeable 
as well. 
 
The FDA and also the EMEA Guidance[73] define highly permeable as having a fraction dose 
absorbed of not less than 90%. The recently adopted WHO Guidelines set a limit of not less 
than 85% of the fraction dose absorbed.[3],[74] 
 
Taking all available evidence into consideration, the data set is not fully conclusive, but 
suggests strongly prednisolone to be highly permeable or very close to highly permeable, 
depending on the criterion set. 
 
Prednisolone has nonlinear pharmacokinetics, which sometimes are seem as a caveat to a 
positive biowaiver decision.[73] Generally speaking, nonlinear pharmacokinetics has little 
relevance to equivalence testing, either in vivo or in vitro, since the test product will have the 
same dose as the reference product. Moreover, most reported in vivo studies include also 
higher doses, for example, 20 mg, indicating also that any nonlinear pharmacokinetics is not 
relevant for the biowaiver decision over the full range of tablet strengths. 
 
BCS Classification 
Kasim et al.[29] classified prednisolone as BCS Class 1. However, their classification is based 
on correlations of partition coefficients with permeability and such correlations have only 
limited predictability. For instance, the correlation of logP with permeability resulted in 8 false 
negatives from 25 predictions and the correlation of ClogP® with permeability resulted in 8 
false negatives and 1 false positive from 28 predictions. Moreover, their correlations are 
based on calculated partition coefficients, not on experimentally measured partition 
coefficients. Lindenberg et al.[75] also classified prednisolone as BCS Class 1. The recently 
adopted revised WHO Guideline classifies prednisolone as BCS Class 1.[3] Wu et al.,[76] 
using the disposition characteristics of the drug for BCS classification, assigned prednisolone 
to BCS Class 1 as well. Indeed, data on solubility, oral absorption, and permeability are not 
totally conclusive, but suggest strongly a BCS Class 1 classification. The lack of reported in 
vitro/in vivo correlations is consistent with that classification.[77] 
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Risks for Bioinequivalence and Surrogate Techniques for In Vivo BE Testing 
What is the risk that bioinequivalent products could be approved if the biowaiver is applied? 
Prednisolone is highly soluble according to the present regulatory guidances.[3],[72-74] So, 
the solubility is not critical and hence the risk of bioinequivalence caused by a difference in 
dissolution in vivo will be very small if the test formulation meets the criteria for in vitro 
dissolution profile similarity to the reference formulation, according to these guidances. In 
principal, bioinequivalence could also be caused by a difference in GI absorption, resulting 
from differences in composition between the test formulation and the reference formulation 
with respect to the excipients. However, prednisolone is on the borderline of highly permeable 
according to the present regulatory guidances[3],[72-74] and so its GI absorption is not 
critical. Hence, the risk of bioinequivalence caused by a difference in permeability will be very 
small. Furthermore, a wide variety of excipients (Table 2) has been used to formulate 
prednisolone IR drug products, having a MA in a number of countries, suggesting that the 
fraction absorbed is not crucially influenced by these excipients. 
 
Risk of Bioinequivalence to the Patient 
Four possible situations could be envisaged resulting from a false biowaiver decision, that is, 
declaring a test formulation bioequivalent to the reference formulation, whereas this test 
formulation would be declared bioinequivalent when subjected to an in vivo BE study. The 
test formulation may give rise to a lower or to a higher AUC and/or to a lower or to a higher 
Cmax than the reference product. 
 
In the first instance, the test formulation has a lower AUC than that of the reference product 
and thus might be clinically less effective. This would have serious clinical consequence only 
in severe, life-threatening diseases that require acute treatment. But such situations require 
high doses, by parenteral administration, that is, such a therapeutic use is highly unlikely with 
oral prednisolone products, especially in the dose range listed by the WHO. A further 
safeguard is that, since prednisolone is a prescription-only drug, therapy will be under 
periodic review by the physician who can adjust the dose or substitute the product if 
necessary. The second situation in which a false biowaiver decision would be clinically 
relevant is when the drug formulation is superbioavailable, that is, the test formulation has a 
higher AUC than the reference. In this situation, the broad therapeutic index of prednisolone 
would protect the patient from very serious side effects, as no serious side effects have been 
observed with this API, even at exceptionally high (acute) doses and serum levels. 
 
Lastly, bioinequivalence caused by a difference in Cmax between the test formulation and the 
reference formulation would have few clinical implications in view of the therapeutic use of 
prednisolone IR tablets, being usually prescribed for patients with chronic diseases. 
 
So, all considerations taken together, there is no reason to classify prednisolone as a Narrow 
Therapeutic Range Drug, which would exclude it from biowaiving according to the FDA and 
EMEA regulation.[72],[73] Also, the requirement of the recently adopted WHO Guideline is 
fulfilled, stating only if the risk of an incorrect biowaiver decision and an evaluation of the 
consequences (of an incorrect, biowaiver-based equivalence decision) in terms of public 
health and risks to individual patients is outweighed by the potential benefits accrued from the 
biowaiver approach may the biowaiver procedure be applied.[74] 
 
CONCLUSION 
 
Data on solubility, oral absorption, and permeability are not totally conclusive, but strongly 
suggest a BCS Class 1 classification for prednisolone. A false biowaiver decision is highly 
unlikely to be reached if the test product fulfills the criteria of dissolution profile similarity in 
three media according to the Guidances.[3],[72-74] A false biowaiver decision is even more 
unlikely if the test product is formulated with the excipients shown in Table 2, in amounts 
usually present in IR solid oral dosage forms. Furthermore, even in the very unlikely situation 
that an incorrect biowaiver decision would be reached, this would not put the patient at undue 
risk. So, when the conditions-mentioned above are all fulfilled, a biowaiver can be 
recommended. 
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This conclusion is in line with the recommendation given by the WHO for biowaiving of 
prednisolone,[3] but is more explicit with respect to the excipients that are acceptable for a 
positive biowaiver decision. 
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